About Selecta Biosciences, Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts. Address: 65 Grove Street, Watertown, MA, United States, 02472
Selecta Biosciences, Inc News and around…
Latest news about Selecta Biosciences, Inc (SELB) common stock and company :
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held
US stock futures traded lower this morning on Thursday ahead of the producer price index. Investors, meanwhile, focused on some notable ...
It is hard to get excited after looking at Selecta Biosciences' (NASDAQ:SELB) recent performance, when its stock has...
Needham has decided to maintain its Buy rating of Selecta Biosciences (NASDAQ:SELB) and lower its price target from $7.00 to ...
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 80.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For ...
– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten offering, raising approximately $38.7 million in gross proceeds, extending runway into mid-2024 – – As of April 11, 2022, Selecta had approximately $154.2 million in cash, cash equivalents, restricted cash and marketable securities – – Selecta to host conference call today at 8:30 AM ET –
Selecta Biosciences (NASDAQ:SELB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors ...
During Wednesday's trading, 435 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: The ...
Selecta Biosciences (NASDAQ:SELB) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings ...
Data to be featured in two oral presentations and four poster presentationsWATERTOWN, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, power gene therapies and mitigate unwanted immune responses to biologics, today announced six upcoming presentations, including three joint presentations with our partner AskBio, at the 25th Annual
Gainers Regulus Therapeutics (NASDAQ:RGLS) stock rose 7.6% to $0.22 during Thursday's pre-market session. The market ...
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, May 5, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate in the live cal
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca In-Licenses ...
WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its common stock and accompanying warrants to purchase up to 20,571,429 shares of common stock at a combined offering price of $1.41 per share and accompanying warrant. The warrants to purchase shares of c
WATERTOWN, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the 21st Annual Needham Virtual Healthcare Conference, to be held virtually April 11-14, 2022. 21st Annual Needham Virtual Healt
On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The ...
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week ...
According to Benzinga Pro, during Q4, Selecta Biosciences (NASDAQ:SELB) earned $12.24 million, a 168.4% increase from the preceding ...
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 42.86% and 49.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences (NASDAQ:SELB) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what ...
– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune tolerance (ImmTOR-IL)- -Further validated and expanded the ImmTOR precision immune tolerance platform through numerous strategic collaborations - -Completed enrollment in DISSOLVE I, the first of two studies
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share ...
Selecta Biosciences (NASDAQ:SELB) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors ...
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 207.14% and 3.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech ...
Biotech stocks reversed course in the week endingMarch 4, as the Ukrainian crisis weighed down on the broader market as well as ...
WATERTOWN, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR®, to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, March 10, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021 and provide a business u
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week ...
Selecta Biosciences, Inc (SELB) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
